MCGI and the TAPUR™ Study

The Targeted Agent Profiling and Utilization Registry (TAPUR™) Study is designed to evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about potential additional uses of these drugs outside of Food and Drug Administration (FDA) approved indications. It provides a clinical trial opportunity for patients with advanced cancer with tumors that have genomic alterations that can be targeted with a TAPUR Study drug. TAPUR is sponsored by the American Society of Clinical Oncology (ASCO), which represents nearly 45,000 oncology professionals around the world who care for people living with cancer. ASCO works to conquer cancer through research, education, and promotion of the highest quality and equitable patient care.

MCGI Brings TAPUR Study to the Northeast

The TAPUR Study is available in a number of largely urban community-based oncology practices, and with this collaboration, JAX enables Maine and New Hampshire to join the TAPUR Study as the first rural states in the Northeast at a statewide level. The TAPUR Study is now enrolling patients at the following locations as part of MCGI:

• Maine Health — Maine Medical Center
• MaineGeneral Medical Center — Harold Alfond Center for Cancer Care
• New England Care Specialists
• New Hampshire Oncology-Hematology
• Northern Light Health
• York Hospital

The TAPUR Study is now enrolling. Visit the TAPUR website at tapur.org or email [email protected] for more information.